Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $224.50, for a total transaction of $32,552.50. Following the completion of the transaction, the senior vice president now directly owns 7,411 shares in the company, valued at approximately $1,663,769.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Charles Dadswell also recently made the following trade(s):

  • On Monday, December 4th, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $225.33, for a total transaction of $32,672.85.
  • On Friday, November 3rd, Charles Dadswell sold 1,609 shares of Illumina stock. The shares were sold at an average price of $207.88, for a total transaction of $334,478.92.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up $2.67 during mid-day trading on Thursday, reaching $232.99. 860,600 shares of the company’s stock were exchanged, compared to its average volume of 801,399. Illumina, Inc. has a twelve month low of $130.25 and a twelve month high of $233.54. The stock has a market capitalization of $34,020.00, a PE ratio of 43.96, a P/E/G ratio of 3.07 and a beta of 0.79. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the prior year, the company earned $0.97 earnings per share. The firm’s revenue was up 17.6% on a year-over-year basis. sell-side analysts predict that Illumina, Inc. will post 3.75 earnings per share for the current year.

ILMN has been the subject of a number of recent research reports. Leerink Swann reiterated an “outperform” rating and issued a $225.00 price objective (up from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Argus raised their price target on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 price target for the company in a report on Tuesday, September 19th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $200.00 price objective on shares of Illumina in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $226.00 price objective (up from $202.00) on shares of Illumina in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $207.74.

A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. Winslow Capital Management LLC bought a new position in Illumina during the second quarter valued at $211,584,000. HPM Partners LLC lifted its position in Illumina by 29,103.8% during the second quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after purchasing an additional 749,424 shares during the last quarter. Fred Alger Management Inc. lifted its position in Illumina by 611.9% during the second quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after purchasing an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Capital World Investors lifted its holdings in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. 91.60% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) SVP Sells $32,552.50 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/illumina-inc-ilmn-svp-sells-32552-50-in-stock.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.